StockData
Rocket Pharmaceuticals, Inc. logo

Rocket Pharmaceuticals, Inc. (RCKT) stock

RCKTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 3/30
$2.11−0.05 (-2.31%)

Close on Nov 17, 2026Market cap $231.62MP/E –Yield –

Rocket Pharmaceuticals ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Rocket Pharmaceuticals's ebitda for the twelve months ending Jun 30, 2026 was -$184.04M. For fiscal 2025 it was -$222.85M. The highest annual figure on record is -$70.83M in fiscal 2018.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$222.85M–
FY2024Dec 31, 2024-$266.01M–
FY2023Dec 31, 2023-$254.76M–
FY2022Dec 31, 2022-$220.44M–
FY2021Dec 31, 2021-$164.05M–
FY2020Dec 31, 2020-$133.16M–
FY2019Dec 31, 2019-$75.73M–
FY2018Dec 31, 2018-$70.83M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$45.32M–
Q1 FY2026Mar 31, 2026-$46.91M–
Q4 FY2025Dec 31, 2025-$42.26M–
Q3 FY2025Sep 30, 2025-$49.55M–
Q2 FY2025Jun 30, 2025-$69.15M–
Q1 FY2025Mar 31, 2025-$61.89M–
Q4 FY2024Dec 31, 2024-$60.89M–
Q3 FY2024Sep 30, 2024-$67.52M–
Q2 FY2024Jun 30, 2024-$71.91M–
Q1 FY2024Mar 31, 2024-$65.68M–
Q4 FY2023Dec 31, 2023-$61.88M–
Q3 FY2023Sep 30, 2023-$64.23M–
Q2 FY2023Jun 30, 2023-$67.56M–
Q1 FY2023Mar 31, 2023-$61.09M–
Q4 FY2021Dec 31, 2021-$43.32M–
Q3 FY2021Sep 30, 2021-$48.85M–
Q2 FY2021Jun 30, 2021-$33.35M–
Q1 FY2021Mar 31, 2021-$38.55M–
Q4 FY2020Dec 31, 2020-$58.61M–
Q3 FY2020Sep 30, 2020-$27.09M–
Q2 FY2020Jun 30, 2020-$23.46M–
Q1 FY2020Mar 31, 2020-$24.00M–
Q4 FY2019Dec 31, 2019-$19.55M–
Q3 FY2019Sep 30, 2019-$19.07M–

More Rocket Pharmaceuticals figures

See a number that looks wrong?